ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
67 011,26
-0,10%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Boundless Bio Inc (BOLD)

  7. Boundless Bio Inc (BOLD) Actualités

BOLD

Boundless Bio (BOLD)

Boundless Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BOLD
DateHeureSourceTitreSymboleSociété
13/05/202413h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLDBoundless Bio Inc
13/05/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLDBoundless Bio Inc
13/05/202413h00Business WireBoundless Bio Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BOLDBoundless Bio Inc
06/05/202414h00Business WireBoundless Bio to Present at the Citizens JMP Life Sciences Conference 2024NASDAQ:BOLDBoundless Bio Inc
11/04/202414h00Business WireBoundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsNASDAQ:BOLDBoundless Bio Inc
08/04/202414h00Business WireBoundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024NASDAQ:BOLDBoundless Bio Inc
14/02/202023h23Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BOLDBoundless Bio Inc
11/02/202022h41Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:BOLDBoundless Bio Inc
27/01/202015h38Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:BOLDBoundless Bio Inc
21/01/202012h00Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BOLDBoundless Bio Inc
04/12/201901h13PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.NASDAQ:BOLDBoundless Bio Inc
03/12/201900h01Business WireAstellas Enters into Definitive Agreement to Acquire Audentes TherapeuticsNASDAQ:BOLDBoundless Bio Inc
26/11/201922h01Business WireAudentes Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:BOLDBoundless Bio Inc
12/11/201923h33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BOLDBoundless Bio Inc
07/11/201923h18Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BOLDBoundless Bio Inc
07/11/201922h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BOLDBoundless Bio Inc
07/11/201922h01Business WireAudentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:BOLDBoundless Bio Inc
31/10/201912h00Business WireAudentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2...NASDAQ:BOLDBoundless Bio Inc
05/10/201913h01Business WireAudentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked M...NASDAQ:BOLDBoundless Bio Inc
05/10/201900h00Business WireAudentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BOLDBoundless Bio Inc
30/09/201914h00Business WireAudentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including Ne...NASDAQ:BOLDBoundless Bio Inc
23/08/201922h03Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:BOLDBoundless Bio Inc
06/08/201922h01PR Newswire (US)Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:BOLDBoundless Bio Inc
30/07/201914h00PR Newswire (US)Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 201...NASDAQ:BOLDBoundless Bio Inc
17/07/201922h25Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BOLDBoundless Bio Inc
29/05/201922h01PR Newswire (US)Audentes Therapeutics Announces Changes to Senior Management TeamNASDAQ:BOLDBoundless Bio Inc
13/05/201912h04Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BOLDBoundless Bio Inc
08/05/201914h00PR Newswire (US)Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care ConferenceNASDAQ:BOLDBoundless Bio Inc
07/05/201922h01PR Newswire (US)Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:BOLDBoundless Bio Inc
01/05/201920h15PR Newswire (US)Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular M...NASDAQ:BOLDBoundless Bio Inc
 Showing the most relevant articles for your search:NASDAQ:BOLD

Dernières Valeurs Consultées

USOTC
UBETF
UBS ETF Shares Holdings ... (GM)
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés